Pharmacia gets Xalcom approvable letter

Pharmacia Corp has received its second approvable letter from the USFood and Drug Administration regarding its fixed-dose glaucoma product Xalcom (latanoprost plus timolol). The company originally filed for marketing clearance of Xalcom in December last year and received its first approvable letter in June (Marketletter June 19).

Although not disclosed, Pharmacia says that it will "continue to work with the FDA to resolve outstanding issues regarding Xalcom."

- Meantime, the firm says that one-year data from a Phase III trial of SnET2 (tin ethyl etiopurpurin) could be available during the first half of 2001. Pharmacia is planning to file for regulatory approval of SnET2, a photodynamic therapy for the treatment of "wet" age-related macular degeneration, by the end of the year (Marketletter July 31).